Skip to content
lifestyle.folsomlocalnews.com/
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
argenx SE
argenx Reports Half Year 2026 Financial Results and Provides Second Quarter Business Update
July 23, 2026
argenx to Report Half Year 2026 Financial Results and Second Quarter Business Update on July 23, 2026
July 16, 2026
argenx to Host Autoimmune Myositis R&D Webinar
June 23, 2026
argenx Presents New Efgartigimod Data Showing Long-Term Sustained Patient Benefit in Myositis and Sjogren’s Disease at EULAR 2026
June 4, 2026
argenx to Present at Upcoming Investor Conferences
May 27, 2026
argenx Announces U.S. FDA Approval Expanding VYVGART and VYVGART Hytrulo for Use in All Adult Patients Living with gMG
May 8, 2026
argenx Reports First Quarter 2026 Financial Results and Provides Business Update
May 7, 2026
argenx to Present at BofA Securities 2026 Health Care Conference
May 6, 2026
argenx Announces Results of Annual General Meeting and Board of Directors’ Appointment of Karen Massey as Chief Executive Officer
May 6, 2026
argenx to Report First Quarter 2026 Financial Results and Business Update on May 7, 2026
April 30, 2026
1
2
Next Page
→